2.25 USD
-0.14 (-5.86%)
2.26 USD
+0.01 (+0.44%)
Overall IBIO gets a fundamental rating of 2 out of 10. We evaluated IBIO against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of IBIO have multiple concerns. IBIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year IBIO has reported negative net income.
- IBIO had a negative operating cash flow in the past year.
- In the past 5 years IBIO always reported negative net income.
- IBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -79.26%, IBIO is not doing good in the industry: 66.29% of the companies in the same industry are doing better.
- With a Return On Equity value of -123.50%, IBIO is not doing good in the industry: 60.19% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.26% | ||
| ROE | -123.5% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for IBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -18.85, we must say that IBIO is in the distress zone and has some risk of bankruptcy.
- IBIO has a Altman-Z score of -18.85. This is amonst the worse of the industry: IBIO underperforms 81.52% of its industry peers.
- IBIO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
- IBIO has a Debt to Equity ratio (0.05) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.85 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- A Current Ratio of 1.59 indicates that IBIO should not have too much problems paying its short term obligations.
- The Current ratio of IBIO (1.59) is worse than 79.81% of its industry peers.
- IBIO has a Quick Ratio of 1.59. This is a normal value and indicates that IBIO is financially healthy and should not expect problems in meeting its short term obligations.
- IBIO has a Quick ratio of 1.59. This is in the lower half of the industry: IBIO underperforms 79.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 73.07% over the past year.
- The Revenue has grown by 77.78% in the past year. This is a very strong growth!
- Measured over the past years, IBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 11.09% on average over the next years. This is quite good.
- Based on estimates for the next years, IBIO will show a small growth in Revenue. The Revenue will grow by 4.56% on average per year.
EPS Next Y81.54%
EPS Next 2Y35.73%
EPS Next 3Y22.02%
EPS Next 5Y11.09%
Revenue Next Year-25%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IBIO. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as IBIO's earnings are expected to grow with 22.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.73%
EPS Next 3Y22.02%
5. Dividend
5.1 Amount
- No dividends for IBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IBIO INC / IBIO FAQ
What is the ChartMill fundamental rating of IBIO INC (IBIO) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IBIO.
What is the valuation status for IBIO stock?
ChartMill assigns a valuation rating of 1 / 10 to IBIO INC (IBIO). This can be considered as Overvalued.
Can you provide the profitability details for IBIO INC?
IBIO INC (IBIO) has a profitability rating of 0 / 10.